FREMONT, Calif., Jan. 31, 2017 -- MEDABLE Inc. has been recognized as one of the Top 10 Analytics Solution Providers by Pharma Tech Outlook Magazine.
|
|||
“We take pride in honoring MEDABLE as one among the 10 companies that are specialized in providing Analytics solutions for Pharmaceutical Companies,” said Stacey Smith, Managing Editor of Pharma Tech Outlook. “Medable is the most secure platform in healthcare and the only globally compliant cloud solution in healthcare.”
Medable provides the fastest path to a HIPAA compliant healthcare application. Medable's platform provides all the healthcare applications features with the flexibility to support customer’s creative vision.
About MEDABLE
Medable is a privately held company based in Palo Alto. Medable’s products enable healthcare innovation. Medable Cortex is the fastest path to scalable, interoperable, HIPAA compliant applications. Medable Axon is the world's first SmartStudy technology that enables health experts to directly create and launch applications. Medable Cerebrum enables secure analytics across Medable apps on Cortex, Axon or third party backend systems for real-time algorithm-driven patient monitoring and health data visualization. For more info, visit: www.medable.com
About Pharma Tech Outlook
Published from Fremont, California, Pharma Tech Outlook is a print magazine that covers most important and latest developments in pharmaceutical industry. A panel of experts and members of Pharma Tech Outlook’s editorial board selected and finalized the “Top 10 Analytics Solution Providers 2017” and shortlisted the best vendors and consultants. For more info: www.pharmatechoutlook.com
Gary Poole, PR Director [email protected]


South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 



